Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs
about
Tricyclic antidepressant pharmacology and therapeutic drug interactions updatedApplications of CYP450 testing in the clinical settingA new therapeutic option for postoperative pain management with oxycodone HCI injectionAugmentation with antidepressants in schizophrenia treatment: benefit or riskAbiraterone in the treatment of metastatic castration-resistant prostate cancerPolymorphisms in the human cytochrome P450 and arylamine N-acetyltransferase: susceptibility to head and neck cancersGenetics of Common Antipsychotic-Induced Adverse EffectsPharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug responseA systematically combined genotype and functional combination analysis of CYP2E1, CYP2D6, CYP2C9, CYP2C19 in different geographic areas of mainland China--a basis for personalized therapyMolecular Dynamics Simulations to Investigate the Influences of Amino Acid Mutations on Protein Three-Dimensional Structures of Cytochrome P450 2D6.1, 2, 10, 14A, 51, and 62Dextromethorphan and quinidine combination for heroin detoxification.Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines.Towards the clinical implementation of pharmacogenetics in bipolar disorder.Pharmacogenetics of antipsychotics.Practical guide to the use of abiraterone in castration resistant prostate cancer.Pharmacogenetics of antidepressant response.Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates.Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disordersSerotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders.BJCP 40th anniversary: moving forward, looking back.Personalizing health care: feasibility and future implications.Pharmacogenetics of antidepressantsPredicting response to lithium in mood disorders: role of genetic polymorphisms.Pharmacogenetics of the major polymorphic metabolizing enzymes.Human pharmacogenomic variations and their implications for antifungal efficacy.Pharmacogenomics--how close/far are we to practising individualized medicine for children?Pharmacogenetics of monoamine transporters.The promise and reality of pharmacogenetics in psychiatryThe AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.Pharmacogenetics of antipsychotic-induced side effectsUtilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors.CYP2D6 polymorphisms in patients with porphyriasPharmacogenetics of cytochrome p4502D6: genetic background and clinical implication.Farnesoid X Receptor Agonist Represses Cytochrome P450 2D6 Expression by Upregulating Small Heterodimer Partner.Neuropsychiatric pharmacogenetics: moving toward a comprehensive understanding of predicting risks and response.From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community.The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects.Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes.Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.Influence of CYP2D6 polymorphisms on symptomatology and side-effects of patients with schizophrenia in Malaysia
P2860
Q24564967-05920C81-C687-4BCE-98D9-93B501936999Q24621760-83D9687C-94BC-4CBC-941C-E5E611E66A65Q26747676-8A85EFD4-E23A-4643-886B-6E66EDD4A8F1Q26851841-13ED7940-646F-4379-A5A5-8D4A54298D1CQ26853635-A1B29308-D013-4F4A-B2A2-0F78BCE4C5F5Q27010137-C4AC7784-C2EA-4825-9F06-F1F5FC2290A2Q28072893-904071DF-BFBA-4E2D-B3D1-A420A36B633BQ28252209-139FBD89-6218-4094-A655-6BB04837DF58Q28533992-85C703FC-C1BF-4547-A1C8-35649F6D8C2BQ28551168-774F0EEF-C2C3-4C99-8509-517E1953323FQ30418597-49119E64-318E-405A-B45A-6289D2EA8552Q33232404-49AC419C-0B87-4A9F-8EF6-1837B6618CC3Q33688133-DB9DDEDC-1655-411C-B241-8CFDBE0E398AQ33836837-65E17891-8C30-4C30-A80C-1612564F90F9Q34070638-FBFF5970-BA16-4232-90FE-A7657AB74186Q34155796-5BA667B2-1057-41A3-9F96-BD6958062CDAQ34331552-38736547-C5C7-4366-A60D-4657A46C822CQ34391577-53B9BFFE-5DE5-4E96-80AA-343370239FF0Q34473840-A0C99924-7148-459B-9E4B-A15E54EF1366Q34635476-398F5318-57A1-4592-A0D6-07099B106A87Q34938911-3BB51DBE-3B69-4E14-BC8A-CF09B6163743Q35026088-D88095CD-616C-4A1E-86E0-C4B3DD7D011AQ35058020-114D9665-9935-48FE-A308-C53B7EDA4328Q35067187-8B56D8A9-5CA4-4727-BB70-C27BAFA3BBCBQ35070838-69C890DF-F06D-47E5-AF5C-965AABE45665Q35135951-3DA40550-A952-4408-B56C-AE6703DE4722Q35207551-799E2161-D218-4D23-9986-13F0E0E699E7Q35226451-2C54812E-A730-4215-932B-0483048B33D7Q35236618-F8DD20D3-5DE2-4447-95F8-4B55258AFD40Q35237129-21E78B1C-ABE4-4FB8-BD21-CAD65D66DC58Q35558099-EB86CB48-FDE5-4A83-AC39-A9A037E91E8FQ35586929-8A989939-29A4-4461-899E-74CA16CF46C3Q35594563-E7302234-9DB9-4AFE-BA90-313E6997D1DDQ35745253-27A791AF-D8D3-4041-86C9-187F4CD9442EQ35814369-A9D1CB40-E52C-4B3B-8FB7-DABB0577103CQ35814384-77A4228E-DF8A-47D1-9693-299F16EA58B7Q35827277-1A922C03-43A7-4E08-8F4A-119E15BD96CAQ35873687-1829D85C-9EF1-4847-A2B6-82253A86280DQ35876954-D53EBCBD-6EC5-4976-ADF0-101C92EF4736Q35896386-EE49E630-E247-4C0B-84B5-3A4A45EC85A0
P2860
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs
@ast
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs
@en
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs
@nl
type
label
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs
@ast
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs
@en
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs
@nl
prefLabel
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs
@ast
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs
@en
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs
@nl
P2093
P2860
P3181
P1476
Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs
@en
P2093
Ayman Al-Shurbaji
Marja-Liisa Dahl
P2860
P304
P3181
P356
10.1046/J.0306-5251.2001.01548.X
P407
P577
2002-02-01T00:00:00Z